Medicine Redefined 195. Menopause Hormone Therapy: What the WHI Got Wrong and What the FDA Finally Fixed | Lauren Spivack, MD
Mar 2, 2026
Dr. Lauren Spivack, board-certified OB-GYN and menopause specialist with fellowship training in minimally invasive gynecologic surgery, discusses what went wrong with the WHI and why the FDA changed estrogen labeling. She covers the timing window for hormone therapy, the newly named musculoskeletal syndrome of menopause, differences in formulations and dosing, vaginal estrogen, progesterone strategies, and testosterone use in women.
AI Snips
Chapters
Books
Transcript
Episode notes
Vaginal Estrogen For GSM Works And Is Safe
- Use vaginal (topical) estrogen for genitourinary syndrome of menopause to treat dryness, burning, dyspareunia, and recurrent UTIs.
- Typical regimen: loading nightly short-term then maintenance twice weekly; it's very safe even when systemic HRT is contraindicated.
Choose Transdermal When Clot Or Vascular Risk Exists
- Prefer transdermal estrogen (patch/gel/spray) for patients with clot risk, smokers, migraine with aura, or cardiovascular risk.
- Transdermal avoids first-pass hepatic metabolism and minimizes added VTE/stroke risk compared with oral estrogen.
Practical Starting Doses For Systemic Estrogen
- Start standard systemic HRT doses modestly: oral estradiol ~1 mg or patch 0.05 mg as equivalents.
- Use lower starting doses (pill 0.5 mg or patch 0.025 mg) for older or higher-risk patients and titrate to symptom relief.
